Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
PCSK9- Single Domain Antibody Inhibitor
AmorChem Canada flag Canada
Abstract ID:
We have identified a number of single domain antibodies (sdAbs) which bind PCSK9. sdAbs provide an interesting novel modality to bind this target and are more cost effective than mAbs to manufacture....
Contact John Clement
Participants
You
Email me a copy of this message

Hyperlipidemia is a predominant risk factor for cardiovascular disease (CVD). Mutation in low-density lipoprotein receptor ( LDLR) or apolipoprotein B (ApoB) genes are major causes of familial hypercholesterolemia. Proprotein convertase subtilisin/kexin type 9 (PCSK9) was a third gene involved in this familial disease and plays an important role in the metabolism of low-density lipoprotein cholesterol (LDL-c). PCSK9 degrades the LDL-receptor, improves the lipoprotein profile and future cardiovascular outcomes in patients with dyslipidemia.

Recent Phase 2 clinical data (Amgen) obtained using antibodies to block its action show up to 60% reduction in levels of LDL-c. However, there are no single domain antibodies under development for this target. We believe this product could position itself quite competitively in the biological landscape; providing the specificity of monoclonal antibodies but at the fraction of the price.

GO PREMIUM TO GET PATENT INFORMATION
Type of Business Relationship Sought
Out-licensing or collaboration
FEATURED
Last Updated Jun 2016
Technology Type PLATFORM
Phase of Development EARLY STAGE
CORPORATION